New Delhi, Aug 5: Drug major Lupin on Wednesday announced the launch of its Favipiravir drug under the brand name 'Covihalt' for the treatment patients with mild to moderate COVID-19 symptoms at Rs 49 per tablet in India.

Favipiravir has received authorisation from the Drug Controller General of India (DCGI) for emergency use, Lupin said in a regulatory filing.

Also Read | PM Narendra Modi Presented With a Headgear, Silver 'Mukut' & Stole by Sri Gaddinsheen Premdas Maharaj: Live News Breaking And Coronavirus Updates on August 5, 2020.

Its Covihalt dosage strength has been developed keeping in mind convenience of administration, it stated, adding that the drug is available as 200 mg tablets in the form of a strip of 10 tablets, and priced at Rs 49 per tablet.

Lupin President - India Region Formulations (IRF) Rajeev Sibal said the company believes that it can leverage its expertise in managing widespread community diseases like tuberculosis to proactively reach patients across India and ensure access to Covihalt through its strong distribution network and field force.

Also Read | Ram Mandir Bhumi Pujan Live News Updates From Ayodhya: PM Narendra Modi Lands in Ayodhya, to Lay Foundation Stone Shortly.

On August 4, Sun Pharmaceutical Industries had launched Favipiravir under the brand name ''FluGuard'' for the treatment of mild to moderate cases of COVID-19, at Rs 35 per tablet in India. Shares of Lupin were trading 0.32 per cent higher at Rs 943.70 apiece on BSE.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)